Combination of quinoline-4-carboxamides and benzonaphthyridine derivatives as antimalarial drug combination

US11491162B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Thomas Spangenberg · Wellesley, US
• Claude Oeuvray · Paris, FR
• Nada Abla · Carouge, CH

Key dates

• Filing date: Apr 9, 2019
• Grant date: Nov 8, 2022
• Expiry date: Jun 6, 2039

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A combination includes as a first active ingredient 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide or a prodrug or pharmaceutically acceptable salt thereof and as a second active ingredient pyronaridine or a prodrug or pharmaceutically acceptable salt thereof. Also, a combination includes three antimalarial active ingredients, namely of 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide or a prodrug or salt thereof, pyronaridine or pharmaceutically acceptable salt thereof, and artemisinin or derivatives thereof. Further, pharmaceutical compositions include such combination. The combinations and pharmaceutical compositions are useful for the treatment and/or prevention of malaria.